Summary
NEW YORK - Abbott Laboratories on Monday said it would pay $6.6 billion for the pharmaceutical business of Belgian chemicals maker Solvay in a move to further expand internationally and add to its product portfolio.
By purchasing Brussels-based Solvay, Abbott gains access to emerging markets in Eastern Europe and Asia along with new therapeutic areas, including hormone therapies and vaccines.See the full content of this document
Extract
Abbott Buys Belgian Company
Solvay's flu va...
See the full content of this document
Sponsored links
